Lysarc
            21 December 2017
          
        French Cooperative Groups in Oncology
Focus on their Contribution to the Fight against Cancer

LYSA and LYSARC as founding members of the French Cooperative Groups in Oncology are delighted to present the last brochure on “The academic clinical research activity of French Cooperative Groups in the fight against cancer”.
This brochure focuses on some examples of therapeutic advances. In the lymphoma field and particularly in the mantle cell lymphoma, a study* conducted in the LYSA centers showed that the addition of rituximab immunotherapy after intensive chemotherapy has improved patient survival.
Download the brochure (in French)
* Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. S. Le Gouill et al. N Engl J Med 2017; 377:1250-60.
News
          16 July 2025 Lysarc
        
                    LYSA-LYSARC 2024 interactive activity report
                    The LYSA-LYSARC group publishes its interactive activity report for the yea...
          
          03 April 2025 Lysarc
        
                    LYSARC in Nature Cancer: Hope Post-CAR-T
                    
          
          15 September 2023 Lysarc
        
                    Publication of ALYCANTE study in Nature Medic...
                    LYSA-LYSARC announces the publication in Nature Medicine of  the ALYCANTE s...
          